Cubist Pharma Q2 Revenue Increases 29%
Cubist Pharma said that the increase was attributable primarily to its net sales of Cubicin (daptomycin for injection) in the US, which increased 23% to $155m from $126.1m
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for chronic lymphocytic leukaemia (CLL) treatment in low- and middle-income countries until 2028.